Loading...
13 North America Hyperglycemics Reports
Region Covered: North America
Study Period: 2019 - 2029
Countries Covered: United States, Canada
Major Players: Janssen Pharmaceutical, Eli Lilly, AstraZeneca Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Astellas
Region Covered: North America
Study Period: 2019- 2029
Countries Covered: United States, Canada
Major Players: Sanofi Aventis, Bristol-Myers Squibb, Glenmark Pharmaceuticals, Takeda Pharmaceuticals, Merck & Co., Inc.
Region Covered: North America
Study Period: 2019 - 2029
Countries Covered: United States, Canada
Major Players: Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc, Biocon Limited
Region Covered: North America
Study Period: 2018 - 2029
Countries Covered: United States, Canada
Major Players: Novo Nordisk, Glenmark, Novartis, KISSEI, Biocon
Region Covered: North America
Study Period: 2018 - 2029
Countries Covered: United States, Canada
Major Players: Mylan, Lupin, Merck and Co., Pfizer Inc., Sanofi Aventis
Region Covered: North America
Study Period: 2019- 2029
Countries Covered: United States, Canada, Germany, Spain, Italy, France, United Kingdom, Russia, Japan, China, Australia, India, South Korea, Malaysia, Indonesia, Thailand, Vietnam, Philippines, Brazil, Mexico, South Africa, Saudi Arabia, Oman, Egypt, Iran
Major Players: Glenmark Pharmaceuticals, Novartis, Kissei Pharmaceuticals, Biocon, Novo Nordisk A/S
Region Covered: North America
Study Period: 2019 - 2029
Countries Covered: United States, Canada, France, Germany, Italy, Spain, United Kingdom, Russia, Mexico, Brazil, Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand, Saudi Arabia, Iran, Egypt, Oman, South Africa
Major Players: Janssen Pharmaceuticals, Eli Lilly, Bristol Myers Squibb, AstraZeneca Pharmaceuticals, Astellas
Region Covered: North America
Study Period: 2019 - 2029
Countries Covered: United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, Australia, South Korea, South Africa, Brazil, Argentina
Major Players: Abbott, Sanofi , Mylan Inc, Lupin, Aurobindo Pharma
Region Covered: North America
Study Period: 2018 - 2029
Countries Covered: United States, Canada, France, Germany, Italy, Spain, United Kingdom, Russia, Mexico, Brazil, Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand, Saudi Arabia, Iran, Egypt, Oman, South Africa
Major Players: Sanofi Aventis, Novo Nordisk AS, Biocon, Eli Lilly and Company, Julphar
Region Covered: North America
Study Period: 2019 - 2029
Countries Covered: United States, Canada, Germany, Spain, Italy, France, United Kingdom, Russia, Japan, China, Australia, India, South Korea, Malaysia, Indonesia, Thailand, Philippines, Vietnam, Brazil, Mexico, South Africa, Saudi Arabia, Oman, Egypt, Iran
Major Players: Novo Nordisk, Sanofi, Eli Lilly, Biocon, Wockhardt
Region Covered: North America
Study Period: 2019 - 2029
Countries Covered: United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, Australia, South Korea, South Africa, Brazil, Argentina
Major Players: Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Sanofi, Biocon
Region Covered: North America
Study Period: 2019- 2029
Countries Covered: United States, Canada, France, Germany, Italy, Spain, United Kingdom, Russia, Mexico, Brazil, Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand, Saudi Arabia, Iran, Egypt, Oman, South Africa
Major Players: Sanofi Aventis, Pfizer Inc., Merck & Co., Inc., Torrent Pharma, Dr. Reddy's Laboratories
Region Covered: North America
Study Period: 2018 - 2029
Countries Covered: United States, Canada, Germany, Spain, Italy, France, United Kingdom, Russia, Japan, China, Australia, India, South Korea, Malaysia, Indonesia, Thailand, Philippines, Vietnam, Brazil, Mexico, South Africa, Saudi Arabia, Oman, Egypt, Iran
Major Players: Bristol Myers Squibb, Glenmark Pharmaceuticals, Takeda, Sanofi Aventis, Merck and Co.
Filter Reports
By Countries
